Blood Journals Portfolio/LinkedIn
Sep 9, 2025, 23:00
Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
In this episode, “Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor” the methodology of three articles are discussed that feature sickle cell disease studies.
Key points are:
- Ruxolitinib plus Dexamethasone in Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis (HLH): A prospective study demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients. All patients responded to the treatment, and no significant adverse effects were observed.
- Lysine-Specific Demethylase-1 (LSD1) Inhibitors in Sickle Cell Disease: Novel, potent, and orally bioavailable LSD1 inhibitors have been shown to induce fetal hemoglobin synthesis in a sickle cell disease mouse model. These inhibitors effectively reduce reactive oxygen species and improve red blood cell lifespan, offering a promising new class of therapies for sickle cell disease and other beta-globinopathies.
- Clinical Characteristics of Patients with Low Von Willebrand Factor: Insights into the clinical phenotype and pathophysiological mechanisms underlying qualitative low von Willebrand factor (VWF) have been explored. Patients with plasma VWF levels between 30 to 50 IU/dL often present with mucocutaneous bleeding and may require tailored management strategies.
Listen to the full episode here.
What are your thoughts on these advancements in sickle cell disease research?”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Jan 27, 2026, 13:48Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA
-
Jan 27, 2026, 12:27Martin Haluzík on Residual Cardiovascular Risk in Coronary Artery Disease
-
Jan 27, 2026, 12:18Stuart Phillips: Strong Bodies Are Good, Informed Bodies Are Better!
-
Jan 27, 2026, 12:07Daniel Torrent: This Should Be An Ice Cold Take… But Veins Aren’t Arteries
-
Jan 27, 2026, 09:17Paolo Zamboni on CCSVI Associated to Multiple Sclerosis
-
Jan 27, 2026, 09:02Rowan Paul: Platelet Dose Determines Success in PRP Therapy
-
Jan 27, 2026, 08:48Uriel Suárez: Hemi‐Orolingual Angioedema in a Patient With VEXAS Syndrome
-
Jan 27, 2026, 08:23Rossella Crescitelli on Platelets’ and PEVs’ Association with Lung Cancer Metastases
-
Jan 27, 2026, 08:11Matthew Flick Links Urokinase Plasminogen Activator Deficiency to Obesity